Kornimate/medical-research-clean huggingface dataset:
lifu for chronic pain

Conditions: Chronic Pain

Summary: this research project is examining the effects of noninvasive brain stimulation on chronic pain. we believe this study will help us to better understand possible treatments for chronic pain patients. subjects will undergo functional magnetic resonance imaging (fmri) and a computed tomography (ct) scan, which is a way to take pictures of the brain and skull. subjects will receive noninvasive brain stimulation using low-intensity focused ultrasound (lifu) sound waves, to temporarily change brain activity. subjects will undergo pain testing using a small device that will increase the temperature of their skin and will rate this pain. brain signals (eeg), heart rate and rhythm, blood pressure, respiration rate, and skin moisture will be monitored. subjects will complete behavioral questionnaires. each study session is expected to take 1.5-3 hours. total participation takes 10 weeks.

this is a 2-arm, sham-controlled, cross-over design. this study is collected over 5-7 study visits. initial imaging (1): mri and ct scans, questionnaires, and qst testing. intervention (2): sham or verum lifu application every 10 minutes, totaling in 8 applications. between lifu or sham application quantitative sensory testing (qst) will be performed. physiological data collection such as eeg, eda, bp, ecg, and respiration will be collected throughout the study visit. follow-up imaging (2-4): following intervention sessions participants will receive a resting-state mri. this can occur throughout the 4-weeks following an intervention visit. participants will be scanned at least once after each intervention session. follow-up virtual questionnaires: following intervention sessions participants will receive a link (or a phone call if preferred) to periodically rate their pain and report on various lifestyle impacts of their chronic pain. participants will complete these questionnaires at least twice per week in the 2 weeks following an intervention visit. these questionnaires will take less than 30 minutes. after completing the intervention and minimum 4-week washout period, the participant will return for a second intervention visit and 3 week follow-up period.

Eligibility criteria:
inclusion criteria: * patients with a chronic pain diagnosis. pain must be moderate-to-severe and present for at least 3 months prior to research participation. patients of all ethnicities, who understand and speak english. exclusion criteria: * claustrophobia (scanning environment may be uncomfortable). * contraindications to mri: including pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, or other implants. * contraindications to ct: pregnancy * active medical disorder or treatment with potential cns effects (e.g. alzheimer\&#39;s) * history of neurologic disorder. (e.g. parkinson\&#39;s, epilepsy, or essential tremor) * history of head injury resulting in loss of consciousness for \&gt;10 minutes. * history of alcohol or drug dependence (through self-report).

Keywords: low-intensity focused ultrasound lifu tfus
role of routine on-table cholangiography in laparoscopic cholecystectomy

Conditions: Common Bile Duct Stones

Summary: the purpose of this study is to assess whether routine imaging of the biliary system during routine gallbladder surgery alters clinical outcome


Eligibility criteria:
inclusion criteria: * all patients over the age of 18 with biliary colic or cholecystitis exclusion criteria: * any history of allergic reaction to contrast material * patients with abnormal liver function test results * any clinical history of jaundice * patients with a history of pancreatitis * patients with a history of previous ercp * patients whose ultrasound showed common bile duct or intra-hepatic duct dilation * all patients with previous major upper abdominal surgery * all patients with acalculous cholecystitis or gallbladder polyps

Keywords: gallstones cholangiography
distribution circumferential versus non circumferential of mepivacaine in the median and ulnar nerves

Conditions: Anesthesia

Summary: 1. evaluation of the efficacy of the circumferential versus non circumferential distribution of mepivacaine around the median and ulnar nerves. 2. evaluation the onset of action of mepivacaine in circumferential versus non circumferential distribution around the median and ulnar nerves. 3. spread of mepivacaine after injection guided by ultrasonography. 4. complications of both anesthetic techniques in postoperative time.


Eligibility criteria:
inclusion criteria: * scheduled patients for surgery of carpal tunnel including patients in asa i-iii status, without exclusion criteria. the principal investigator study and/or other designated site staff will obtain written informed consent from all research patients. exclusion criteria: * abnormal bleeding, infection in the punction side, allergy or other problems with the medication of the study, muscular or nerve diseases, patients \< 18 years old, pregnancy, cognitive disease or reject of the patient

Keywords: ultrasonography block nerve anaesthesia carpal tunnel syndrome
personalized rtms for resistant depression

Conditions: Depressive Disorder; Treatment-Resistant

Summary: the investigators hypothesize that personalizing the rtms targets using functional mri will increase its efficacy. the most dysfunctional regions or the most dysfunctional network will be stimulated homogeneously. individualized rtms will be compared to traditional rtms procedure and to trans-cranial direct current stimulation (tdcs) in a randomized cross-over trial. in this pilot study the primary outcome measure will be the correction of the mri anomalies. symptoms reduction and the proportion of remitters will be secondary outcome measurements.


Eligibility criteria:
inclusion criteria: * aged from 18 to 65 y * affiliated to the health insurance * having signed an informed consent * suffering from major depression according to the dsm5 * unresponsive or incomplete remission after at least one trial of antidepressant (\> 6 weeks at efficient dose or side effects) * treatment stable for \> 6 weeks exclusion criteria: * contraindication for mri, rtms or tdcs: non-removable ferromagnetic body, prosthesis, pacemaker, medication delivered by an implanted pump clip or vascular stent, heart valve or ventricular shunt, seizure disorders, skin pathology in the region of tdcs electrode placement. * pregnancy * severe and non-stabilized somatic pathology * patients deprived of liberty or hospitalized without their consent

Keywords: individualized medicine transcranial magnetic stimulation, repetitive transcranial direct current stimulation monocentric compariative cross-over 3 arms study randomized, single-blind method functional neuroimaging
effects of telmisartan on ischemic cardiovascular events in high-risk hypertensive patients

Conditions: Acute Myocardial Infarction; Angina Pectoris; Myocardial Ischemia; Acute Coronary Syndrome; Hypertension

Summary: this study is aimed to investigate whether treatment with telmisartan is more effective than candesartan in reducing the ischemic cardiovascular events in high-risk patients with cardiovascular disease.

this study is aimed to investigate whether treatment with telmisartan is more effective than candesartan in reducing the ischemic cardiovascular events in high-risk patients with cardiovascular disease. study design: probe(prospective, randomized, open-labeled blind endpoints)

Eligibility criteria:
inclusion criteria: the inclusion criteria are set by at least one of the three following risk factors: 1. coronary artery disease documented by at least one of the following: * myocardial infarction at least 12 months before enrollment and not planned for percutaneous coronary intervention (pci) or coronary artery bypass grafting (cabg) * angina pectoris or asymptomatic myocardial ischemia undergoing percutaneous coronary intervention (pci) or coronary artery bypass grafting (cabg) at least 12 months before enrollment and not planned for further percutaneous coronary intervention (pci) or coronary artery bypass grafting (cabg) 2. peripheral arterial disease undergoing percutaneous transluminal angioplasty (pta) or peripheral artery bypass grafting at least 6 months before enrollment 3. symptomatic cerebral infarction or cerebral hemorrhage at least 6 months before enrollment exclusion criteria: the exclusion criteria are set as follows: 1. history of worsening of heart failure within the preceding 6 months 2. planned elective percutaneous coronary intervention (pci) or coronary artery bypass grafting (cabg) within the anteceding 3 months 3. history of myocardial infarction, unstable angina pectoris, percutaneous coronary intervention (pci) or coronary artery bypass grafting (cabg) within the preceding 12 months 4. history of percutaneous hind limb angioplasty (pta) or bypass grafting within the preceding 6 months 5. history of cerebral infarction, cerebral hemorrhage within the past 6 months 6. congenital heart disease 7. uncontrolled hypertension on treatment (eg, bp\>180/110 mmhg) 8. pregnant women or women of childbearing potential 9. hepatic dysfunction (ast or alt \>100iu/l) 10. renal impairment (serum creatinine level \>2.0 mg per 100 ml) 11. known hypersensitivity or intolerance to arb

Keywords: angiotensin receptor vulnerable plaque coronary artery
medical clowning: needs assessment and implication for hospitalized children with cancer/blood disease

Conditions: Blood Disease; Cancer; Friendly Healthcare in Children; Medical Clown; Hospitalized Children

Summary: hospitalized children who undergo painful procedures are more susceptible than others to experiencing iatrogenic effects, such as anxiety, pain, and severe stress. clowns in clinical setting have been found to be effective in reducing children's experiences of these effects during hospitalization and before procedures. this article provides an overview of clowning in health care settings; reviews major studies conducted on clowning for hospitalized children, discussing evidence that clown interventions decrease pain and distress in pediatric patients; and concludes with a discussion of health care clowning as a profession.


Eligibility criteria:
inclusion criteria: * aged 4-18 children with cancer/blood disease and parents of children aged 0-18 years with cancer/blood disease exclusion criteria: * older than aged 18
molecular breast imaging in patients with a history of bloody nipple discharge

Conditions: Breast Cancer; Bloody Nipple Discharge

Summary: the purpose of this study is to evaluate molecular breast imaging in the workup of patients with a history of bloody nipple discharge, not reproducible in the office who have a negative clinical breast examination, and a negative diagnostic mammogram and breast ultrasound.

although the cause of bloody nipple discharge is benign in most cases, the evaluation is focused on excluding a malignant cause. when bloody nipple discharge is clinically reproducible, management traditionally involves surgical duct excision. when bloody nipple discharge is not reproducible and mammogram and ultrasound are negative the management relies on "watchful waiting" - serial breast imaging to exclude a focal finding and continued observation for recurrent bloody nipple discharge. this approach provokes anxiety among patients who do not have a clear explanation for the bloody nipple discharge. galactography is useful when positive, but has a high false-negative rate. mri has not been studied in this context and is costly. ductoscopy may play a diagnostic role in the future, but experience and equipment are limiting variables. the availability of a less costly method of excluding breast cancer would be of great value in this population. molecular breast imaging (mbi) is a highly promising novel methodology for breast cancer detection developed under the leadership of dr. michael o'connor at mayo clinic, rochester, mn. preliminary patient studies with our dual-detector system indicate that this system is capable of reliably detecting very small (5-10 mm) malignant lesions in the breast.

Eligibility criteria:
inclusion criteria: * women age 25 - 75 * women with a negative diagnostic mammogram and ultrasound * women with a history of bloody nipple discharge which can not be reproduced by the examining physician or the patient in the office exclusion criteria: * pregnant or lactating * unable to understand or sign a consent form * physically unable to sit upright and still for 40 minutes

Keywords: mbi mammogram breast cancer breast ultrasound bloody nipple discharge molecular breast imaging
efficacy of massage in stroke spasticity

Conditions: Stroke; Sequelae

Summary: stroke is one of the common diseases in the elderly. it is the third ranking cause of death and affects health care system in our country. one of the most important consequences of stroke is spasticity. some stroke patients suffered from severe spasticity or hypersensitive reflex to stimuli. it can cause contracture, limit self care function, transfer or ambulation. most of stroke patients have to depend on their relatives or families.

thai traditional massage is one of the popular alternative medicine in thailand. lots of stroke patients who suffered from spasticity sought treatment. to the investigators knowledge, there is no study concerning efficacy of massage in decreasing spasticity for stroke patients.

Eligibility criteria:
inclusion criteria: * stroke with onset of \>=6 months * age \>=50 years * spasticity grade of knee flexor or elbow flexor was 2-3 classified by modified ashworth scale (mas) * ability to follow command and communicable exclusion criteria: * having contraindications for massage including fever \> 38 degree, uncontrolled blood pressure, bleeding tendency, on anticoagulant drug, having ulcer or healing fracture of limbs, contamination skin disease, severe osteoporosis * serious contact diseases, for example aids, tb * history of malignancy * fixed joint contracture at elbow or knee of paralyzed limb * history of botulinum toxin injection or phenol/alcohol nerve block within 3 months * previous history of ttm * severe dementia or uncontrolled psychiatric problems

Keywords: massage stroke spasticity
development of cellular models for osteoblast response study to adipocytic secretions in an osteoporosis context.

Conditions: Osteoporosis

Summary: the recent studies suggest that secretions from medullary adipocytes are involved in the mechanisms of bone loss in osteoporosis (op) through their actions on neighbouring osteoforming cells, the osteoblasts. the objective of the research is the development of new cellular models representing the aging skeleton to confirm this hypothesis. to this end, osteoblasts will be isolated from human bone fragments coming from femoral heads discarded during total hip replacement surgery. the osteoblastic response to secreted factors released from medullary adipocytes of commercial origin will be analysed using conditioned media incubations. this phenotypic response will be quantified for each subject through the analysis of gene expression levels. inter-subject phenotype variations will be related to bone density and microarchitecture data obtained by x-ray microtomography. this will assess the existence of a correlation between the osteoblast response to adipocyte secretions and the degree of osteoporosis of the subject from whom the cells are derived.


Eligibility criteria:
inclusion criteria: * adult subject * surgical indication for hip prosthesis implantation * affiliation to a social insurance regime exclusion criteria: * rejection of participation * diagnosed bone diseases other than osteoarthritis or osteoporosis * cancer * pregnant women * subject under guardianship or trusteeship * subject unable to understand the study.

Keywords: bone osteoporosis osteoblast adipocyte cellular models
study of botulinum toxin in patients with primary hyperhidrosis

Conditions: Hyperhidrosis

Summary: objectives: i. determine the optimal dose of botulinum toxin necessary to decrease sweating in patients with primary hyperhidrosis.

protocol outline: patients receive injections of botulinum toxin in the clinical trial for 6 months. patients undergo an iodine starch test and a sympathetic skin response test to assess the efficacy of the drug. patients also complete questionnaires to evaluate the amount of sweating.

Eligibility criteria:
* diagnosis of hyperhidrosis * excessive sweating in the hands, feet, armpits, forehead, or body

Keywords: dermatologic disorders hyperhidrosis rare disease
validation and comparison of scores for prediction of risk for post-operative major morbidity after cholecystectomy in acute calculous cholecystitis (sprimacc)

Conditions: Acute Cholecystitis

Summary: the sprimacc study is a prospective multicenter observational study with the primary endpoint to prospectively validate the chole-risk score in predicting a complicated postoperative course (post-operative major complications (clavien-dindo\>=3a), length of stay (los) \> 10 days or need of readmission within 30 days from the discharge) in patients undergoing early cholecystectomy (ec) for acute calculous cholecystitis (acc). the secondary endpoints of the study are to prospectively validate and compare other wellknown risk prediction models (the possum/p-possum score, the modified frailty index (mfi), the charlson comorbidity index (cci), the american society of anesthesiologists (asa) score and the apache ii score) in predicting a complicated post-operative course in patients undergoing ec.


Eligibility criteria:
inclusion criteria: * have a diagnosis of acute calculous cholecystitis (acc) as defined by tokyo guidelines 2018 criteria * be candidate to early cholecystectomy (ec) during the index admission\* * be ≥ 18 years old * be stratified for the risk of common bile duct stones (cbds) according to the israelian score, and, in case of confirmation of cbds receive pre-operative endoscopic retrograde cholangiopancreatography (ercp). * provide signed and dated informed consent form * willing to comply with all study procedures and be available for the duration of the study. * all the patients treated with initial open cholecystectomy, those who undergo early laparoscopic cholecystectomy (elc), those with conversion from laparoscopic to open cholecystectomy or those who undergo bail out procedures (e.g. subtotal cholecystectomy) will be included. exclusion criteria: * pregnancy or lactation * acute cholecystitis not related to a gallstone etiology * onset of symptoms \>10 days before cholecystectomy\*\* * concomitant cholangitis or pancreatitis * intraoperative treatment of common bile duct stones * anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study. * patients with acc associated with common bile duct stones who underwent pre-operative ercp could be included if they receive ec within 10 days from onset of symptoms
predictive study of serum endocan for hemorrhagic transformation after reperfusion therapies in acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: stroke is the second largest cause of death globally after ischemic heart disease.of the total number of prevalent strokes, 84.4% are ischemic. reperfusion therapy is the most important treatment for acute ischemic stroke (ais) ,including intravenous thrombolysis and/or endovascular treatment.however,the most serious and common complication with reperfusion therapy is hemorrhage transformation(ht),which significantly increases disability and mortality. the fundamental mechanism leading to post-stroke ht is the disruption of the blood brain barrier(bbb) and increase of permeability.endocan plays a critical role in vascular inflammatory responses by enhances the production of pro-inflammatory cytokines by endothelial cells,the expression of adhesion molecules such as inter-cellular adhesion molecule-1(icam-1) and vascular cell adhesion molecule-1(vcam-1),and the adhesion of leukocytes to endothelial cells. endocan significantly decreases levels of zonula occludens（zo-1) and occludin which are tight junction proteins that play major roles in the maintenance of vascular barriers. endocan could induce vascular endothelial growth factor-a(vegf-a) and facilitate the binding of vegf-a to its receptor(vegfr-2) to enhanced endothelial permeability.therefore,endocan is a reliable biomarker of endothelial dysfunction, which may be associated with disruption of the bbb. in this context, the investigators hypothesized that elevated pretreatment serum endocan levels might be independently associated with ht after reperfusion therapy in the acute phase of ischemic stroke. serum endocan,icam-1,vcam-1 and matrix metalloproteinase-9(mmp-9) levels will be determined by enzyme-linked immunosorbent assay(elisa) in blood samples obtained at baseline (pretreatment) and at 12,24 hours after reperfusion therapy in patients with acute stroke and in healthy subjects.in the present study,the investigators attempt to investigate whether high levels of endocan are associated with ht in patients who received reperfusion therapy.in addition,the investigators explore the association between serum endocan and early neurological deterioration and unfavourable short-term prognosis.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of acute ischemic stroke and presentation at the hospital within 24h from symptom onset * eligibility for intravenous thrombolysis and/or endovascular treatment * age ≥18 years exclusion criteria: * administration of intravenous thrombolysis at another hospital in patients who are candidates for endovascular treatment * contraindications to intravenous thrombolysis * contraindications to iodinated contrast agent * a history of ischemic stroke in three months * clinical diagnosis of autoimmune,inflammatory, hematological, or infectious diseases * clinical diagnosis of cancer * clinical diagnosis of severe cardiac,pulmonary,renal or liver failure * clinical diagnosis of dementia or psychosis * pregnant and lactating women

Keywords: endocan stroke reperfusion hemorrhage
perioperative administration of pregabalin for pain after robot-assisted endoscopic thyroidectomy

Conditions: Pain, Postoperative

Summary: the investigators hypothesize that pregabalin will decrease post-operative pain scores and analgesic use following robot-assisted endoscopic thyroidectomy compared to placebo. the primary outcome will be acute postoperative pain, measured by a verbal numerical rating score (vnrs) and total analgesic consumption during postoperative 48 hours. the secondary outcome will be the incidence of chronic pain and hypoesthesia in the anterior chest at 3 months after operation.


Eligibility criteria:
inclusion criteria: 1. american society of anesthesia physical status class i \& ii 2. age ≥ 20 and ≤ 65 years 3. robot- assisted endoscopic thyroidectomy exclusion criteria: 1. known or suspected allergy, sensitivity, or contraindication to pregabalin or any of the standardized medications 2. body mass index ≥ 40 kg/m2 3. history of seizure disorder 4. current therapy with pregabalin, gabapentin, or any opioid 5. any other physical or psychiatric condition which may impair their ability to cooperate with post-operative study data collection 6. insulin-dependent diabetes mellitus 7. renal insufficiency (estimated glomerular filtration rate (egfr) \< 60 ml/min/1.73 m2)

Keywords: thyroidectomy pain, postoperative pregabalin